Metformax (Metformin Hydrochloride)

Metformin reduces the liver’s production of glucose, decreases absorption of glucose from the intestine, and enhances the sensitivity of muscle cells to insulin. These combined actions lower circulating glucose levels without causing the pancreas to release more insulin.

The dosage of Metformax is individualized by the prescribing clinician based on the patient’s medical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule.

Metformax is generally not recommended for routine use during pregnancy unless the potential benefit outweighs the risk. It is excreted in breast milk in small amounts, so clinicians usually advise against breastfeeding while on metformin unless deemed necessary.

To request Metformax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Metformax (metformin) differs from sulfonylureas and meglitinides by not stimulating insulin secretion, which reduces the risk of hypoglycaemia. Compared with newer agents such as SGLT2 inhibitors or GLP‑1 receptor agonists, metformin is less expensive and has a long safety record, though it may be less potent in lowering HbA1c for some patients.

Metformax tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children.

Metformax is taken orally, usually with meals to minimise gastrointestinal upset. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

The most serious potential adverse effect of Metformax is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformax is contraindicated in individuals with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients receiving radiographic contrast studies unless renal function is closely monitored.